SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Sustainability and affordability of cancer drugs: a novel pricing model · Study

ArticleShelves

ArticleSustainability and affordability of cancer drugs: a novel pricing model

Carin A. Uyl‐de Groot2018

Article2018

Sustainability and affordability of cancer drugs: a novel pricing model

Carin A. Uyl‐de Groot · Bob Löwenberg

77 citations·0/0 files stored·Nature Reviews Clinical Oncology

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Health Systems, Economic Evaluations, Quality of Life Economic and Financial Impacts of Cancer

Abstract

No abstract was published for this record.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 77 citations exist upstream.

References

2016Innovation in the pharmaceutical industry: New estimates of R&D costs 2013Economic burden of cancer across the European Union: a population-based cost analysis 2014Thresholds for the cost–effectiveness of interventions: alternative approaches 2017Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 2017Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

Cited by

2021Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications 2020What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings 2020Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe 2020Integrative Review of Managed Entry Agreements: Chances and Limitations 2021Evidence-based public policy making for medicines across countries: findings and implications for the future 2020Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer

Related works

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

2019Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companiesarticle · 3 shared references 2020Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018article · 2 shared references 2021How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessmentreview · 2 shared references 2018Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016article · 2 shared references 2024Costs of Drug Development and Research and Development Intensity in the US, 2000-2018article · 2 shared references 2018Financial toxicity and implications for cancer care in the era of molecular and immune therapiesreview · 2 shared references

Details

Year2018

Typearticle

Published2018-05-04

VenueNature Reviews Clinical Oncology

ISSN-L1759-4774

Languageen

Citations77

Files0 public / 0

ShelfPharmaceutical Economics and Policy

Identifiers

doi10.1038/s41571-018-0027-x

openalex_workW2801910361

Links

Imported from OpenAlex (CC0) — nothing here is generated.